Using artificial intelligence to design safer nanoparticles for targeted drug delivery
Official title: Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety
Funded at Methodist Hospital Research Institute · NIH-10855721 · Data updated 2026-11-12
This study is working on making tiny particles that can deliver medicine right where it's needed in the body, using smart computer technology to help design them better, so patients can get safer and more effective treatments with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 9, 2024 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $391,588 |
| NIH project number | 1R01EB035545-01 |
| Project ID | NIH-10855721 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals requiring targeted therapies for conditions that could benefit from nanoparticle-based drug delivery.
✕Less likely to help
Patients who do not require targeted drug delivery or those with conditions that are not addressed by nanoparticle therapies may not benefit from this research.
What this research studies
This research focuses on improving the design of nanoparticles (NPs) to enhance their ability to deliver drugs directly to specific organs while minimizing side effects. By utilizing artificial intelligence, the researchers aim to create a model that predicts how these nanoparticles behave in the body based on their structure and other factors. This approach involves analyzing existing data and conducting experiments to validate the model's predictions, ultimately leading to safer and more effective treatments for patients. The goal is to streamline the development of new nanomaterials for clinical use.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer drug delivery systems for patients, reducing side effects and improving treatment outcomes.
How similar studies have gone: Previous research has shown promise in using artificial intelligence for drug delivery systems, indicating potential for success in this novel approach.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Dogra, Prashant — Methodist Hospital Research Institute
- Study coordinator: Dogra, Prashant
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Cefazolin Inoculum Effect and MSSA Bacteremia: A Rapid Test to Guide Therapy
A study to understand how a high bacterial load affects cefazolin treatment for serious Staphylococcus aureus infections and to test a quick lab method that helps doctors choose the best antibiotic.
-
Cefazolin Inoculum Effect: How this test could improve care for MSSA bloodstream infections
This project tests a quick lab test to find a specific cefazolin resistance pattern in MSSA blood infections so doctors can choose safer, more effective treatment.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
How brain connections guide visual choices in ADHD
A research study aims to understand how specific brain pathways help people with ADHD make visual decisions, using non-invasive methods in primates.
-
Why some Klebsiella pneumoniae infections resist key carbapenem antibiotics
This project looks at why certain Klebsiella pneumoniae infections resist carbapenem antibiotics and how those infections affect adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.